BioAge Labs is rated 'Hold' after a rally driven by BGE-102 Phase 1 data and Eli Lilly's Ventyx acquisition. Click to read my ...
EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback